Table 3.
Multivariable Analysis of RAI Use for Stage I Thyroid Cancer
| Proportion treated with RAI at hospital (Mean % ± SD) |
Multivariable P value | ||
|---|---|---|---|
| Hospital Characteristics | |||
| Case Volume | |||
| Low | 40.13 ± 25.66 | 0.002 | |
| Low-Mod | 48.63 ± 21.97 | 0.518 | |
| Moderate | 44.29 ± 20.14 | 0.075 | |
| High | 48.48 ± 17.75 | Ref. | |
| Practice Setting | |||
| Academic | 44.91 ± 17.34 | Ref. | |
| Community based academic affiliate | 44.09 ± 19.52 | 0.715 | |
| Private | 46.48 ± 22.92 | 0.036 | |
| Decision-making process | |||
| Access to tumor board | |||
| Yes | 47.57 ± 20.50 | 0.006 | |
| No | 42.55 ± 22.04 | Ref. | |
| No. of providers administering RAI | |||
| 3 or more | 47.47 ± 19.21 | Ref. | |
| 2 | 48.76 ± 19.46 | 0.694 | |
| 1 | 44.55 ± 25.01 | 0.010 | |
| 0 | 29.28 ± 22.63 | <0.001 | |
| Primary decision maker on whether or not to administer RAI | |||
| Surgeon | 42.29 ± 21.57 | <0.001 | |
| Endocrinologist | 45.42 ± 20.37 | <0.001 | |
| NM/Radiol/Other | 52.50 ± 23.05 | Ref. | |
RAI = radioactive iodine, NM = nuclear medicine provider